As reported on BioSpace, Eli Lilly is moving closer to expanding the use of its oral GLP‑1 receptor agonist orforglipron, marketed as Foundayo, into type 2 diabetes (T2D), following encouraging results from multiple late-stage clinical trials. The company plans to submit the therapy for regulatory approval in T2D after demonstrating consistent improvements in blood glucose control and weight reduction across several Phase 3 studies presented at the 2026 American Diabetes Association (ADA) Scientific Sessions.
Robust Glycemic Control Across ACHIEVE Trials
The findings come from the ACHIEVE clinical program, which evaluated orforglipron in patients with inadequately controlled T2D despite background treatments such as metformin or insulin. Across the trials, the oral therapy produced greater reductions in HbA1c—a key marker of long-term glucose control—compared with both active comparators and placebo.
In the head-to-head ACHIEVE-3 study, orforglipron outperformed Novo Nordisk’s oral semaglutide. At 52 weeks, patients receiving a mid-range dose of the Lilly drug experienced nearly a two-percentage-point decline in HbA1c, compared with just over one percentage point for semaglutide. Higher doses of orforglipron further widened this gap, underscoring a dose-dependent effect on glycemic control.
Additional studies reinforced these findings. In ACHIEVE-2, orforglipron demonstrated superior glucose lowering compared with AstraZeneca’s SGLT2 inhibitor dapagliflozin (Farxiga). Meanwhile, ACHIEVE-5 showed meaningful HbA1c reductions when the drug was added to insulin glargine, outperforming a control regimen of insulin plus placebo.
Weight Loss Benefits Strengthen Value Proposition
Beyond glycemic improvements, orforglipron also delivered notable weight loss, an increasingly important factor in T2D management. In ACHIEVE-3, patients receiving higher-dose orforglipron achieved substantially greater weight reduction than those treated with oral semaglutide. These dual benefits—lower blood glucose and reduced body weight—support the drug’s positioning as a comprehensive metabolic therapy.
Analysts note that consistent performance across different study designs and patient populations enhances confidence in orforglipron’s broader applicability. Its oral administration and once-daily dosing may also improve patient adherence compared to injectable GLP‑1 therapies.
Competitive Landscape and Market Dynamics
The positive data intensify competition between Eli Lilly and Novo Nordisk, the dominant players in the GLP‑1 space. While Lilly has demonstrated strong efficacy in diabetes-focused comparisons, Novo retains an advantage in the obesity market, where its oral semaglutide formulation has shown greater weight loss in longer-term studies. Notably, direct comparative trials between the two drugs for obesity indications have not been conducted, limiting cross-trial conclusions.
Despite this, Lilly’s progress in T2D could secure a meaningful share of the oral GLP‑1 market, particularly as demand grows for non-injectable treatment options. Market analysts suggest there is room for multiple therapies, given the scale of the diabetes population and the ongoing need for improved glycemic control strategies.
Regulatory Outlook
Lilly is expected to file for T2D approval of orforglipron in the second quarter of 2026. If approved, the drug would expand beyond its current indication in weight management, marking a significant milestone in its lifecycle.
The momentum seen in the ACHIEVE program positions orforglipron as a strong contender in oral diabetes therapeutics. As the GLP‑1 class continues to reshape metabolic care, the upcoming regulatory review will be closely watched to determine how this latest entrant fits into an increasingly competitive landscape.
